{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T23:08:28Z","timestamp":1788736108132,"version":"build-2803163510"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctrv.2026.103193","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T04:54:03Z","timestamp":1783918443000},"page":"103193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunotherapy for locally advanced head and neck squamous cell carcinoma: A review"],"prefix":"10.1016","volume":"149","author":[{"given":"Robert","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pascal","family":"Machiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Borgovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arindam","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103193_bb0005","article-title":"Locally advanced head and neck squamous cell carcinoma treatment efficacy and safety: a systematic review and network meta-analysis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and neck cancer","volume":"382","author":"Chow","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103193_bb0015","series-title":"Global cancer observatory: Cancer today","author":"Ferlay","year":"2024"},{"key":"10.1016\/j.ctrv.2026.103193_bb0020","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/medsci11020042","article-title":"Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma","volume":"11","author":"Barsouk","year":"2023","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.ctrv.2026.103193_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17030357","article-title":"Risk stratification in HPV-associated oropharyngeal cancer: limitations of current approaches and the search for better solutions","volume":"17","author":"Garb","year":"2025","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctrv.2026.103193_bb0035","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ctrv.2026.103193_bb0040","first-page":"9352","article-title":"Molecular morphology and function of stromal cells","volume":"24","author":"Manetti","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2026.103193_bb0045","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/00220345241271992","article-title":"A review of immunotherapy for head and neck Cancer","volume":"103","author":"Goetz","year":"2024","journal-title":"J Dent Res"},{"key":"10.1016\/j.ctrv.2026.103193_bb0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41568-022-00531-9","article-title":"Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment","volume":"23","author":"Ruffin","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2026.103193_bb0055","series-title":"Summary of product characteristics","author":"Pembrolizumab","year":"2025"},{"key":"10.1016\/j.ctrv.2026.103193_bb0060","series-title":"Nivolumab US prescribing information","author":"Bristol-Myers Squib","year":"2025"},{"key":"10.1016\/j.ctrv.2026.103193_bb0065","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103193_bb0070","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103193_bb0075","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1634\/theoncologist.2016-0496","article-title":"FDA approval summary: Pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy","volume":"22","author":"Larkins","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103193_bb0080","series-title":"Pembrolizumab US prescribing information","year":"2025"},{"key":"10.1016\/j.ctrv.2026.103193_bb0085","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103193_bb0090","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0095","doi-asserted-by":"crossref","first-page":"S1399","DOI":"10.1016\/j.annonc.2022.08.029","article-title":"Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)","volume":"33","author":"Machiels","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0100","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","article-title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial","volume":"25","author":"Machiels","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0105","article-title":"Overcoming resistance to standard-of-care therapies for head and neck squamous cell carcinomas","volume":"13","author":"Gauss","year":"2024","journal-title":"Cells (Basel)"},{"key":"10.1016\/j.ctrv.2026.103193_bb0110","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ctrv.2026.103193_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188386","article-title":"Priming the tumor immune microenvironment with chemo(radio)therapy: a systematic review across tumor types","volume":"1874","author":"van den Ende","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.ctrv.2026.103193_bb0120","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1038\/s41467-024-49873-y","article-title":"Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease","volume":"15","author":"Telarovic","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103193_bb0125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.6004\/jnccn.2025.0007","article-title":"NCCN guidelines(R) insights: head and neck cancers, version 2.2025","volume":"23","author":"Colevas","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2026.103193_bb0130","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.jval.2020.04.1807","article-title":"PCN351 real world evidence on patient characteristics and frontline treatment patterns in locally advanced squamous cell carcinoma of the head and neck from Europe and US","volume":"23","author":"Tarallo","year":"2025","journal-title":"Value Health"},{"key":"10.1016\/j.ctrv.2026.103193_bb0135","unstructured":"NCCN. National Comprehensive Cancer Network\u00ae (NCCN\u00ae) Guidelines Version 2.2025. National Comprehensive Cancer Network."},{"key":"10.1016\/j.ctrv.2026.103193_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103018","article-title":"Comparative review of KEYNOTE-689 and NIVOPOSTOP trials and their impact on perioperative immunotherapy in locally advanced head and neck cancer","volume":"140","author":"Imamura","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2026.103193_bb0145","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00405-025-09858-z","article-title":"Optimizing outcomes: a decision-analysis model for oral cancer patients with surgical margins of 1 to 5 mm","volume":"283","author":"Kohler","year":"2026","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0150","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S1470-2045(24)00507-2","article-title":"Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2\/3 trial","volume":"25","author":"Mell","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.05.008","article-title":"Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: assessment from a phase 3 registration trial","volume":"64","author":"Bonner","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103193_bb0160","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-024-05887-z","article-title":"Treatment options for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma: a systematic review","volume":"150","author":"Michelon","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0165","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.21.01293","article-title":"Weekly cisplatin plus radiation for postoperative head and neck Cancer (JCOG1008): a multicenter, noninferiority, phase II\/III randomized controlled trial","volume":"40","author":"Kiyota","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0170","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO-24-01829","article-title":"Postoperative radiotherapy +\/\u2212 Cetuximab for intermediate-risk head and neck Cancer","volume":"43","author":"Machtay","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0175","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103193_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12092080","article-title":"Recurrent versus metastatic head and neck cancer: an evolving landscape and the role of immunotherapy","volume":"12","author":"Belfiore","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.ctrv.2026.103193_bb0185","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jjco\/hyaa268","article-title":"The role of radiotherapy in the age of immunotherapy","volume":"51","author":"Sato","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0190","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0140-6736(25)01850-1","article-title":"Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial","volume":"407","author":"Bourhis","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103193_bb0195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant Pembrolizumab in locally advanced head and neck Cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103193_bb0280","doi-asserted-by":"crossref","first-page":"S1310","DOI":"10.1016\/j.annonc.2021.08.2112","article-title":"LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized phase III GORTEC-REACH trial","volume":"32","author":"Bourhis","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0285","doi-asserted-by":"crossref","first-page":"S616","DOI":"10.1016\/j.annonc.2024.08.915","article-title":"854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): final analysis of randomized phase III GORTEC 2017-01 REACH trial","volume":"35","author":"Tao","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0295","first-page":"S824","article-title":"1317O results from CompARE phase III RCT: neoadjuvant durvalumab plus chemoradiotherapy (CRT) followed by adjuvant durvalumab immunotherapy (IO) vs CRT alone in intermediate and high-risk oropharyngeal cancer (OPC)","volume":"38","author":"Mehanna","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0365","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13063-023-07881-1","article-title":"CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer","volume":"25","author":"Mehanna","year":"2024","journal-title":"Trials"},{"key":"10.1016\/j.ctrv.2026.103193_bb0310","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1200\/JCO.2026.44.16_suppl.6017","volume":"44","author":"Spreafico","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0275","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","article-title":"Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial","volume":"34","author":"Tao","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0290","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1001\/jama.2025.1483","article-title":"Atezolizumab in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomized clinical trial","volume":"333","author":"Haddad","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2026.103193_bb0325","doi-asserted-by":"crossref","first-page":"S655","DOI":"10.1016\/j.annonc.2024.08.2145","article-title":"945TiP JADE: a phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)","volume":"35","author":"Machiels","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0345","author":"GlaxoSmithKline. NCT06256588"},{"key":"10.1016\/j.ctrv.2026.103193_bb0330","doi-asserted-by":"crossref","first-page":"TPS6120","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS6120","article-title":"eVOLVE-HNSCC: a global phase 3 study of volrustomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) following definitive concurrent chemoradiotherapy (cCRT)","volume":"42","author":"Haddad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0350","author":"AstraZeneca. NCT06129864"},{"key":"10.1016\/j.ctrv.2026.103193_bb0200","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1007\/s12325-025-03351-z","article-title":"Meta-analysis to investigate the correlation between event-free survival and overall survival in patients with resectable locally advanced head and neck squamous cell carcinoma","volume":"42","author":"Zheng","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.ctrv.2026.103193_bb0205","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1200\/JCO.2025.43.16_suppl.6012","article-title":"Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): exploratory efficacy analyses of the phase 3 KEYNOTE-689 study","volume":"43","author":"Adkins","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0210","article-title":"Diagnostic predictors of immunotherapy response in head and neck squamous cell carcinoma","volume":"13","author":"Meliante","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ctrv.2026.103193_bb0215","article-title":"Concordance between three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC) in a multicenter study","volume":"12","author":"Guerini Rocco","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ctrv.2026.103193_bb0220","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41379-020-0644-7","article-title":"Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)","volume":"34","author":"de Ruiter","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0225","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/jclinpath-2020-206466","article-title":"Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types","volume":"73","author":"Krigsfeld","year":"2020","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0230","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s41416-019-0449-y","article-title":"Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma","volume":"120","author":"Rasmussen","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2026.103193_bb0235","doi-asserted-by":"crossref","first-page":"LBA2","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA2","article-title":"NIVOPOSTOP (GORTEC 2018-01): a phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse","volume":"43","author":"Bourhis","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0240","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1200\/JCO.2025.43.16_suppl.6013","article-title":"Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC)","volume":"43","author":"Tao","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0245","series-title":"Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC)","author":"Tao","year":"2025"},{"key":"10.1016\/j.ctrv.2026.103193_bb0250","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO-24-01580","article-title":"Randomized phase II study of concurrent versus sequential pembrolizumab in combination with chemoradiation in locally advanced head and neck cancer","volume":"43","author":"Zandberg","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0255","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO-25-01569","article-title":"Chemoradiation +\/\u2212 atezolizumab in limited-stage small cell lung cancer: results of NRG oncology\/alliance LU005","volume":"44","author":"Higgins","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0260","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0265","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0270","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO-25-02726","article-title":"Timing is of the essence: sequencing immune checkpoint blockade and radiotherapy for success in lung Cancer","volume":"44","author":"Keane","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0300","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103193_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.868490","article-title":"Correlation between early time-to-event outcomes and overall survival in patients with locally advanced head and neck squamous cell carcinoma receiving definitive chemoradiation therapy: systematic review and meta-analysis","volume":"12","author":"Black","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102864","article-title":"Current status and future prospects of combined immunotherapy and epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma","volume":"132","author":"Tian","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2026.103193_bb0320","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.3390\/cancers16203488","article-title":"Review of current and future medical treatments in head and neck squamous cell carcinoma","volume":"16","author":"Lee","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103193_bb0335","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14796694.2026.2619653","article-title":"JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC","volume":"22","author":"Siu","year":"2026","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2026.103193_bb0340","series-title":"Safety and efficacy of first-line dostarlimab monotherapy in patients with programmed death ligand 1 (PD-L1)-positive recurrent\/metastatic head and neck squamous cell carcinoma (HNSCC): GALAXIES H&N-202 interim analysis. THNO-10. Faro, Portugal","first-page":"5","author":"Bossi","year":"2025"},{"key":"10.1016\/j.ctrv.2026.103193_bb0355","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41418-024-01272-y","article-title":"Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck","volume":"31","author":"Sanz-Garcia","year":"2024","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.ctrv.2026.103193_bb0360","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2026-CT173","article-title":"Abstract CT173: molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): the MERIDIAN phase II trial","volume":"86","author":"Garcia","year":"2026","journal-title":"Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:30:04Z","timestamp":1788733804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":73,"alternative-id":["S0305737226001076"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103193","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for locally advanced head and neck squamous cell carcinoma: A review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103193"}}